SM-88

DRUG2 trials

Sponsors

Tyme, Inc, Georgetown University

Conditions

Breast CancerHormone Receptor Positive Breast CarcinomaMetastatic Breast Cancer

Phase 1

Study of SM-88 in Advanced Cancers

WithdrawnNCT02562612

Tyme, IncBreast Cancer

Start: 2022-10-31End: 2023-10-31Updated: 2022-07-01

Phase 2

Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer

TerminatedNCT04720664

Georgetown UniversityBreast Cancer, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Cancer

Start: 2021-09-22End: 2023-02-10Updated: 2023-08-28

Related Papers

Abstract 1786: SM-88, D/L-alpha-metyrosine, is a novel anti-cancer agent in estrogen receptor positive breast cancer

Cancer Research2022-06-15